NCT06383078View on ClinicalTrials.gov

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

December 30, 2027

Conditions

Efficacy and Safety

Interventions

DRUG

HR070803

HR070803 60 mg/\^2 D1 over 90 minutes.

DRUG

Oxaliplatin

Oxaliplatin 85 mg/\^2 D1 over 2 hours.

DRUG

Tegafur

initial dose of S-1 is determined according to the body surface area，orally, D1-7.

DRUG

Folinic acid

Folinic acid 400 mg/\^2 D1

DRUG

5-Fluorouracil

5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06383078 - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter